Two aggregators printed on consecutive days, in opposite structures. Royalty Pharma bought Zealand's remaining rusfertide economics outright for $100M, half on closing and half a year later, leaving the seller 0.25% of net sales above $1.5B. HealthCare Royalty took OPKO's mazdutide royalty as security

A royalty is only worth what someone will pay for it, and not everyone who writes those cheques is buying the same thing. The phrase "royalty fund" hides at least five different businesses. One buys finished, marketed royalties and clips the coupon. One funds the last year of

Binney Street Capital is the venture fund of Dana-Farber Cancer Institute, the Boston academic cancer centre. Established in September 2020 and publicly launched in January 2021 as the Institute's first venture fund, it invests in companies built on Dana-Farber intellectual property or co-founded by Dana-

Relation sits at the top of the royalty stack, not the bottom. It holds no approved drug and almost no clinical risk, yet it is quietly assembling a royalty book on medicines that do not exist, across three different deal structures.

An earlier piece on this site, The Landscape of Vaccine Royalties and Royalty Financing, mapped how vaccine royalty streams arise, how they differ from therapeutic royalties, which deals have printed, and how the messenger RNA patent wars redistributed the economics of the pandemic products. It ended on an observation it

A royalty market can fail in three ways. There can be no cash flow, in which case there is nothing to discuss. There can be cash flow and no price, which is the biosimilar case: a stream exists, both sides can see it, and no number satisfies buyer and seller

A royalty market prices duration. A biosimilar is an asset engineered to have none. That single sentence explains most of what follows, but not the part that matters. The absence of a biosimilar royalty market is not a gap waiting to be filled. It is an equilibrium, held in place

The largest story of the week did not happen. The FT reported, and Reuters corroborated, AstraZeneca and Bristol Myers Squibb merger talks near $400B; the market priced it (AZN as much as -9%, BMY +4-6%) and a senior source categorically denied it on Aug 5. Announced M&A

Section 365 of the Bankruptcy Code is the estate's power to reject, assume, or assign the executory contracts a royalty depends on. This is a practitioner's account of how each power reaches a pharmaceutical stream, worked through the filings, at the deal level and the fund